Nissay Asset Management Corp Japan Buys 155,539 Shares of Biogen Inc. $BIIB

Nissay Asset Management Corp Japan lifted its stake in Biogen Inc. (NASDAQ:BIIB) by 522.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,301 shares of the biotechnology company’s stock after buying an additional 155,539 shares during the period. Nissay Asset Management Corp Japan owned approximately 0.13% of Biogen worth $40,036,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of BIIB. Reflection Asset Management bought a new position in shares of Biogen in the fourth quarter worth approximately $25,000. Bell Investment Advisors Inc bought a new stake in Biogen during the 2nd quarter valued at $27,000. WFA of San Diego LLC purchased a new stake in Biogen during the 2nd quarter valued at $32,000. Root Financial Partners LLC boosted its position in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the period. Finally, MV Capital Management Inc. bought a new stake in Biogen in the 4th quarter worth $34,000. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BIIB shares. UBS Group upped their price objective on shares of Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada raised their target price on Biogen from $240.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wedbush boosted their price target on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, HSBC reiterated a “reduce” rating and issued a $157.00 price objective on shares of Biogen in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $227.79.

Biogen Stock Down 1.4%

Shares of NASDAQ:BIIB opened at $218.50 on Friday. Biogen Inc. has a 52-week low of $131.52 and a 52-week high of $222.85. The firm has a market capitalization of $32.28 billion, a P/E ratio of 38.67, a P/E/G ratio of 6.90 and a beta of 0.17. The stock has a 50 day moving average price of $207.81 and a 200-day moving average price of $195.68. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter last year, the business posted $5.47 EPS. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.